Are You suprised



Tara Iyengar, MD

CIRRICULUM VITAE

Ironwood Cancer & Research Centers a Division of Ironwood Physicians, PC

EMPLOYMENT HISTORY

Ironwood Physicians, P.C. 3/1/2013 – Present

Southwest Oncology, P.C. 9/1/2011 – 2/28/2013

Desert Springs Cancer Care 5/1/2011 – 8/1/2011

Time Gap: 11/2010 – 5/2011 Employment contract negotiations & vacation

4/2005 – 7/2005 Relocating from Massachusetts to Iowa

EDUCATION

Medical School/Undergraduate:

2001 BA/MD Rutgers College/Robert Wood Johnson Medical School

Undergraduate Major: Biology Minor: English with honors

Medical School: Alpha Omega Alpha eligible

Post Graduate Education:

2005-2008 Hematology/Oncology Fellowship

University of Iowa Hospitals and Clinics

2001-2004 Internal Medicine Residency

Brown University Rhode Island/Miriam Hospital Program

HOSPITAL APPOINTMENTS

2008 – 2010 Drug Development Scholar, TGen Clinical Research Services at

Scottsdale Healthcare, Scottsdale, AZ

2004-2005 Hospitalist, HealthSouth Braintree Rehabilitation Hospital, Braintree, MA 02184

HONORS

Fellowship:

2007 Divisional Research Award

College:

• Certificate of Academic Achievement (1995 & 1996)

• Dean’s Award for Excellence 1996

• Phi Eta Sigma National Honor Society 1997

• Golden Key Society (National Honor Society) 1996

• Aresty Scholar (Merit Scholarship) 1994-1998

PROFESSIONAL SOCIETIES

2005 American Society of Hematology

2005 American Society of Clinical Oncology

2005 American Society for Blood and Marrow Transplantation

1997 American Medical Women’s Assn/American Medical Students Assn

RESEARCH

Major Research Interests:

CNS Malignancies, Breast Cancer, and Gynecological malignancies

Clinical Trials:

Mega, A., Rajan, T., et al. (Co-Investigator)

Clinical Trial: “Phase I/II study of concurrent intensity modulated radiation therapy with docetaxel and long term androgen deprivation followed by adjuvant docetaxel and estramustine for men with poor prognosis, locally advanced prostate cancer” BrUOG-PROS-96

Closed early due to toxicity.

Abstracts:

Iyengar, T., Hayashi, M. Leopold, C., Smith, BJ, Gingrich, R. Carter, T., deMagalhaes-Silverman, M. High Dose Carmustine (BCNU), Etoposide (VP-16), Cytarabine (Ara-C), and Cyclophosphamide- BVAC with Autologous Transplant in Relapsed and Refractory Hodgkin’s Disease (HD): Long Term Follow-up of 89 Patients. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 8068

T. Iyengar, N. L. Tran, B. A. Armstrong, M. E. Berens. Candidate treatments

of brain metastases suggested from in silico gene expression analysis of

archival primary breast tumor tissue and brain metastases (BM). J Clin

Oncol 27, 2009 (suppl; abstr e22203)

L. Rosen, T. Chen, T. Iyengar, J. Goldman, S. Lahr, C. Chen, D.S. France,

T.C.K. Chan, J. Kazakin, R. Savage, G. Abbadessa, D. Von Hoff. A Phase I

Trial of ARQ 621 in Adult Patients with Solid Tumors. AACR Annual

Meeting Proceedings 2010, Abstract #2750.

A.J. Wagner, R. Tibes, G.I. Shapiro, T. Iyengar, G.D. Demetri, G.J. Weiss, J.

Fridlyand, K.E. Mazina, G.G. Levy, D.D. Von Hoff, and P.M. LoRusso. A First-in-Human Phase I Study to Evaluate the Pan-PI3K Inhibitor GDC 0941 Administered QD or BID in Patients with Advanced Solid Tumors. ESMO Oral Presentation 2010.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download